Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) PT at $3.65

Lucid Diagnostics Inc. (NASDAQ:LUCD) has received an average rating of “Buy” from the five ratings firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $3.65.

A number of equities research analysts have weighed in on the company. BTIG Research lifted their price objective on Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a report on Friday, September 5th. Wall Street Zen raised Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. Ascendiant Capital Markets upped their price target on Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a research report on Friday, June 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Wednesday, August 13th.

Insiders Place Their Bets

In other news, Director Dennis Matheis acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were purchased at an average cost of $1.02 per share, with a total value of $102,000.00. Following the completion of the purchase, the director owned 665,443 shares of the company’s stock, valued at $678,751.86. This represents a 17.69% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LUCD. Alyeska Investment Group L.P. bought a new position in Lucid Diagnostics in the 1st quarter valued at $2,813,000. Geode Capital Management LLC increased its position in Lucid Diagnostics by 420.3% in the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after purchasing an additional 1,274,194 shares during the period. Ghisallo Capital Management LLC bought a new stake in Lucid Diagnostics during the 1st quarter worth about $629,000. XML Financial LLC acquired a new position in Lucid Diagnostics during the 1st quarter valued at about $266,000. Finally, Citadel Advisors LLC bought a new position in shares of Lucid Diagnostics in the 4th quarter valued at about $98,000. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Price Performance

Shares of Lucid Diagnostics stock opened at $1.02 on Tuesday. Lucid Diagnostics has a 52-week low of $0.75 and a 52-week high of $1.80. The firm has a market capitalization of $136.15 million, a PE ratio of -0.86 and a beta of 1.19. The company’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.22.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.